Celgene Corp.

Celgene Corp. is among the world’s largest Biotechnology sector businesses in the world. Celgene Corp.’s employees generate $110.4M in profits on $1.010B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Celgene Corp. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.

Celgene Corp.’s ticker symbol CELG has recently been trading near $58.05 a share. The Celgene Corp. corporate headquarters in Summit, NJ predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.

The significance of market volume is sometimes ignored, but with a total market capitalization of $22.052B ensures sufficient liquidity. With a beta of 0.44, the company is less volatile than the market as a whole. When the average equity moves lower, Celgene Corp. moves less aggressively.